Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.

Saved in:
Bibliographic Details
Title: Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.
Authors: Wichmann CW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Rigopoulos A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., McDonald A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Cao D; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., O'Keefe GJ; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia., Gong SJ; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; School of Engineering and Mathematical Sciences, La Trobe University, Australia., Gan HK; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Pore N; Early Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA., Coats S; Medimmune LLC, Gaithersburg, MD, USA., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
Source: Nuclear medicine and biology [Nucl Med Biol] 2023 Jul-Aug; Vol. 122-123, pp. 108366. Date of Electronic Publication: 2023 Jul 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9304420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9614 (Electronic) Linking ISSN: 09698051 NLM ISO Abbreviation: Nucl Med Biol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-9614
DOI:10.1016/j.nucmedbio.2023.108366